X0306 4 2019-05-03 0 0001054274 Alliqua BioMedical, Inc. ADYX 0001314595 Podlesak Dennis C/O ADYNXX, INC. 100 PINE ST., STE. 500 SAN FRANCISCO CA 94111 1 0 0 0 Common Stock 2019-05-03 4 A 0 85254 A 85254 D Stock Option (Right to Buy) 1.39 2019-05-03 4 A 0 396 A 2022-12-17 Common Stock 396 396 D Stock Option (Right to Buy) 3.06 2019-05-03 4 A 0 55879 A 2026-12-15 Common Stock 55879 55879 D Shares of common stock of the corporation then known as Adynxx, Inc. ("Private Adynxx") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of October 11, 2018, by and among the Issuer, Embark Merger Sub, Inc. and Private Adynxx (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into 0.0359 shares of the Issuer's common stock, after reflecting a reverse stock split at a ratio of one new share for every six shares of common stock outstanding. On December 18, 2012, Reporting Person was granted an option to purchase 11,041 shares of the common stock of Private Adynxx under Private Adynxx's 2010 Equity Incentive Plan at an exercise price of $0.05 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 396 shares of the Issuer's common stock at a per share exercise price of $1.39. This option has fully vested. On December 16, 2016, Reporting Person was granted an option to purchase 1,556,529 shares of the common stock of Private Adynxx under Private Adynxx's Equity Incentive Plan at an exercise price of $0.11 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 55,879 shares of the Issuer's common stock at a per share exercise price of $3.06. Subject to Reporting Person's continued employment, 1/4th of the option vested and became exercisable on December 16, 2017 with the remainder vesting monthly thereafter for a total vesting period of 48 months. Upon a change of control of the Issuer, 100% of any unvested portion of the option will become fully vested and exercisable. /s/ John T. McKenna, Attorney-in-Fact 2019-05-07